such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and ...

which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease.

SCLC is a genetically heterogeneous disease with ... has also been listed on the Nasdaq Global Market under the ticker symbol “AAPG” since January 2025. It is the only company in the world ...

Transformed SCLC from EGFR-mutated LUAD shows a unique mutational profile, complicating treatment approaches and highlighting the need for tailored therapies. Whole exome sequencing revealed ...

as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and Tecentriq. The data showed that ...

To examine the role of the RB-related gene family in lung cancer we analysed the protein expression of the RB gene in cell lines obtained from 83 patients with small cell lung cancer (SCLC ...

“Some of my friends have even asked me, ‘Walton, what’s it like to become a sex symbol at 53 years old?’ And you know what, if I’m being honest, it feels fantastic.” Goggins then ...

Every product on this page was chosen by a Harper's BAZAAR editor. We may earn commission on some of the items you choose to buy. What does it really mean to be “well” in 2025—and who gets ...

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international ...

SCLC accounts for 13% of all lung cancer cases diagnosed in the US. More than 60% of patients with SCLC present with extensive-stage disease and nearly all will die from resistant or relapsed SCLC ...

This symbol replaces the prior symbol of "DMN" under which the Company previously traded. This change comes as Damon continues to build momentum, highlighted by its innovative product offerings ...